Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria

Sanofi (SNY) and partner Regeneron (REGN) announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria (“CSU”) in adults and adolescents aged 12 years and above, who remain symptomatic despite histamine-1 (H1) antihistamine treatment.Following the latest FDA nod, Dupixent became the first new targeted therapy to be approved for CSU in more than a decade. The drug is now approved for seven type II inflammatory diseases in the United States.Dupixent is already approv ...